• Member News

Medicines Discovery Catapult awarded funding to establish Cheshire & Warrington as an international powerhouse for the creation of new medicines

Today [11 August 2020], Medicines Discovery Catapult (MDC) announce that it has been awarded government seedcorn funding; provided through UK Research and Innovation’s flagship £236m Strength in Places Fund, along with project partner Cheshire & Warrington Local Enterprise Partnership (LEP).


Strength in Places Fund proposal to accelerate medicines development via data and digital technology

Cobra Biologics Reveals New Brand Identity

In January 2020, following the completion of a successful acquisition process, Cobra Biologics became part of the Cognate Bioservices family. In the months since, the teams have been working closely to align operations, evolve joint service offerings and to create a distinctive, new brand identity.

Life sciences take Fieldfisher to top of AIM deal league table

Acuris' ECMi report ranks Fieldfisher's equity capital markets practice first for AIM deals by volume and third for overall ECM deal activity on all markets, boosted by a surge of fundraisings for listed healthcare and life sciences businesses during the Covid-19 pandemic.

Angion Enrolls First Patients in Phase 2 Clinical Trial of ANG-3777 in Patients with Acute Lung Injury Associated with COVID-19 Pneumonia

Angion Enrolls First Patients in Phase 2 Clinical Trial of ANG-3777 in Patients with Acute Lung Injury Associated with COVID-19 Pneumonia

£2.5m of Government funding to accelerate delivery of Incubator at Discovery Park

Science Park helping to drive local economic growth with SELEP support

Horizon Discovery introduces single cell RNAseq-linked CRISPR screening service

• CRISPR-based screening technology platform to address critical gaps in target ID and validation • Single cell RNAseq-linked pooled CRISPR screening offers high-quality screening data and biological insight

Coulter Partners secures Chief Executive Officer for Optimapharm

Coulter Partners was delighted to partner recently with Optimapharm to secure the appointment of Dr. Andrew Copestake as Chief Executive Officer. Andrew joins Optimapharm’s executive management team following several months advising the company’s Board of Directors. Optimapharm is a contract research organization managing clinical trials on behalf of leading biotech, pharma and medical devices companies in 22 countries throughout Europe.

CN Bio makes key senior appointments to support international commercial development

Appointments include James Craven as Chief Commercial Officer and Brian Manning as US Head of Sales

Horizon Discovery licenses CHOSOURCE platform to TrueBinding for development and commercialization of multiple biotherapeutics

TrueBinding signs multi-product commercial-use license to develop stable, antibody-expressing cell lines using Horizon’s gene-edited CHO GS knockout